PRESS STATEMENT
For Immediate Release
May 17, 2018
Contact: Meg Hansen, 603.667.8338
mhansen@piersonharleth.com
Montpelier, VT – “It is highly irresponsible for Vermont legislators to promote an idea that will create more avenues for counterfeit drugs in the midst of the opioid epidemic. Patient safety must be our top priority, and our public policies should reinforce — not undermine — that commitment,” said Caitlin Carroll, spokeswoman for Pharmaceutical Research and Manufacturers of America.
Medical fraud (several participating pharmacies were operating illegally and had taken no steps to ensure drug safety), millions in wasted taxpayer funds, federal seizures of shipments, and low participation plagued earlier drug reimportation programs like Minnesota’s RxConnect and Illinois’ I-SaveRx.
“Vermont participated in the ill-fated I-SaveRx for years. A fool learns from his own mistakes. The wise man learns from the mistakes of others. At the expense of Vermont patients and taxpayers, Montpelier decided that it would learn from neither,” said Meg Hansen, VHCF Executive Director.
###
